Mesa Laboratories (MLAB) Projected to Release Earnings on Monday

Key Points

• Mesa Laboratories is expected to report Q1 2027 results before the market opens on August 10, with analysts forecasting earnings of $2.63 per share and revenue of $60.87 million. The company’s earnings call is scheduled for August 12.
• In its previous quarter, Mesa reported EPS of $1.53, missing consensus by $0.25, while revenue of $63.72 million fell short of the $65.21 million estimate.
• The stock recently traded at $100.81, above the consensus price target of $94, while analysts maintain a “Reduce” consensus rating. Mesa also declared a quarterly dividend of $0.16 per share, representing a 0.6% annualized yield.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) is projected to issue its Q1 2027 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of $2.63 per share and revenue of $60.8670 million for the quarter. Investors can check the company's upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 6:00 AM ET.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The firm had revenue of $63.72 million during the quarter, compared to analyst estimates of $65.21 million. During the same quarter in the previous year, the firm posted ($1.31) earnings per share.

Mesa Laboratories Price Performance

Shares of Mesa Laboratories stock opened at $100.81 on Monday. The business has a 50 day simple moving average of $100.30 and a two-hundred day simple moving average of $94.66. Mesa Laboratories has a 12 month low of $55.45 and a 12 month high of $113.99. The stock has a market capitalization of $564.54 million, a P/E ratio of 84.01 and a beta of 0.92. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29.

Mesa Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be paid a $0.16 dividend. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. Mesa Laboratories's payout ratio is currently 53.33%.

Insider Transactions at Mesa Laboratories

In related news, CFO John Sakys sold 2,827 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the sale, the chief financial officer owned 19,785 shares of the company's stock, valued at approximately $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $39,559.00. Following the transaction, the chief accounting officer owned 2,020 shares in the company, valued at approximately $180,790. The trade was a 17.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,277 shares of company stock worth $770,122 in the last ninety days. Insiders own 2.80% of the company's stock.

Institutional Trading of Mesa Laboratories

Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its position in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Mesa Laboratories in the 4th quarter valued at about $27,000. Kestra Advisory Services LLC purchased a new stake in shares of Mesa Laboratories in the 4th quarter valued at approximately $55,000. BNP Paribas Financial Markets increased its holdings in shares of Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock worth $79,000 after buying an additional 684 shares during the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Mesa Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.